// App-Quantinova.ai

SO-3 : Maintenance olaparib in patients aged ≥65 years with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial

Researchers

Presenter

  • H. Kindler

Principal Investigators

  • M. Reni

  • E. Van Cutsem

  • T. Macarulla

  • M. Hall

  • J. Park

  • D. Hochhauser

  • D. Arnold

  • D. Oh

  • A. Reinacher-Schick

  • G. Tortora

  • H. Algl

  • E. O'Reilly

  • D. McGuinness

  • K. Cui

  • K. Schlienger

  • G. Locker

  • T. Golan

Medical Centers

  • University of Chicago, Chicago, IL, United States

  • Hopital Beaujon (AP-HP), Clichy, and University Paris VII, Paris, France

  • San Raffaele Scientific Institute, Milan, Italy

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

  • Vall d Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

  • Samsung Medical Center, Seoul, Korea

  • University College London Hospitals/UCL Cancer Institute, London, United Kingdom

  • Asklepios Tumorzentrum Hamburg, Hamburg, Germany

  • St. Josef-Hospital/Ruhr-University Bochum, Bochum, Germany

  • Azienda Ospedaliera Universitaria Integrata Verona, Verona, and Fondazione Policlinico Universitario Gemelli IRCCS, Rome, Italy

  • Klinikum Rechts der Isar, Department of Nuclear Medicine, Technische Universitaet Muenchen, Munich, Germany

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • AstraZeneca, Gaithersberg, MD, United States,

  • Merck & Co., Inc., Kenilworth, NJ, United States,

  • The Oncology Institute, Sheba Medical Center at Tel-Hashomer, Tel Aviv University, Tel Aviv, Israel

Locations

  • United States

  • France

  • Italy

  • Belgium

  • Spain

  • Republic of South Korea

  • United Kingdom

  • Germany

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Metastatic pancreatic adenocarcinoma

Biomarkers

  • BRCA mutation

Drug/Treatment

  • Olaparib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved